Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera-Reference-Cited by-同舟云学术

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera

Published:2022-02-11 Issue:6581 Volume:375 Page:678-680
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Muik Alexander¹^ORCID,Lui Bonny Gaby¹,Wallisch Ann-Kathrin¹^ORCID,Bacher Maren¹,Mühl Julia¹^ORCID,Reinholz Jonas¹^ORCID,Ozhelvaci Orkun¹^ORCID,Beckmann Nina¹,Güimil Garcia Ramón de la Caridad¹^ORCID,Poran Asaf²^ORCID,Shpyro Svetlana¹,Finlayson Andrew¹^ORCID,Cai Hui³,Yang Qi³^ORCID,Swanson Kena A.³^ORCID,Türeci Özlem¹⁴^ORCID,Şahin Uğur¹⁵^ORCID

Affiliation:

1. BioNTech, An der Goldgrube 12, 55131 Mainz, Germany.

2. BioNTech US, 40 Erie Street, Cambridge, MA 02139, USA.

3. Pfizer, 401 N Middletown Rd., Pearl River, NY 10960, USA.

4. HI-TRON – Helmholtz Institute for Translational Oncology Mainz by DKFZ, Obere Zahlbacherstr. 63, 55131 Mainz, Germany.

5. TRON gGmbH – Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Freiligrathstraße 12, 55131 Mainz, Germany.

Abstract

The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern Omicron (B.1.1.529) has a large number of mutations, especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan (Wuhan-Hu-1 reference strain), Beta (B.1.351), Delta (B.1.617.2), or Omicron pseudoviruses with sera of 51 participants who received two or three doses of the messenger RNA (mRNA)–based COVID-19 vaccine BNT162b2. After two doses, Omicron-neutralizing titers were reduced >22-fold compared with Wuhan-neutralizing titers. One month after the third vaccine dose, Omicron-neutralizing titers were increased 23-fold relative to their levels after two doses and were similar to levels of Wuhan-neutralizing titers after two doses. The requirement of a third vaccine dose to effectively neutralize Omicron was confirmed with sera from a subset of participants using live SARS-CoV-2. These data suggest that three doses of the mRNA vaccine BNT162b2 may protect against Omicron-mediated COVID-19.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference34 articles.

1. WHO Tracking SARS-CoV-2 variants; www.who.int/en/activities/tracking-SARS-CoV-2-variants/.

2. WHO “SARS-CoV-2 Delta variant now dominant in much of European region; efforts must be reinforced to prevent transmission warns WHO Regional Office for Europe and ECDC” (2021); www.euro.who.int/en/media-centre/sections/press-releases/2021/sars-cov-2-delta-variant-now-dominant-in-much-of-european-region-efforts-must-be-reinforced-to-prevent-transmission -warns-who-regional-office-for-europe-and-ecdc.

3. WHO Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) “Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern” (2021); www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.

4. WHO Headquarters WHO Health Emergencies Programme “Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States” (2021); www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states.

5. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Cited by 288 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS-CoV-2 antibodies and their neutralizing capacity against live virus in human milk after COVID-19 infection and vaccination: prospective cohort studies;The American Journal of Clinical Nutrition;2024-02

2. Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern;Frontiers in Immunology;2024-01-22

3. Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian hamsters;PLOS Pathogens;2024-01-10

4. Responses to Common Misconceptions Relating to COVID-19 Variant-Adapted mRNA Vaccines;Vaccines;2024-01-06

5. Immunology of COVID-19;Textbook of SARS-CoV-2 and COVID-19;2024